Search Result

Results for "

and FGFR4

" in MedChemExpress (MCE) Product Catalog:

By Targets:	FGFR (77) Akt (3) AMPK (1) Apoptosis (8) c-Fms (2) DNA/RNA Synthesis (1) Drug Intermediate (1) EGFR (2) ERK (2) Ferroptosis (1) Fluorescent Dye (2) HDAC (1) Isotope-Labeled Compounds (1) mRNA (1) p38 MAPK (1) PERK (1) Reactive Oxygen Species (ROS) (1) Reference Standards (9) Small Interfering RNA (siRNA) (3)
By Research Areas:	Cancer (74) Inflammation/Immunology (1) Metabolic Disease (5) Neurological Disease (1)
Oligonucleotides:	Rat Pre-designed siRNA Sets (1) mRNA (1) Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (1) Antisense Oligonucleotides (5) siRNAs (3)

Inhibitors & Agonists

Biochemical Assay Reagents

Inhibitory Antibodies

Isotope-Labeled Compounds

Oligonucleotides

Targets Recommended: FGFR

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-13311

Infigratinib Maximum Cited Publications 47 Publications Verification BGJ-398; NVP-BGJ398	FGFR Apoptosis	Cancer
Infigratinib (BGJ-398; NVP-BGJ398) is a potent inhibitor of the *FGFR* family with IC₅₀s of 0.9 nM, 1.4 nM, 1 nM, and 60 nM for *FGFR1, FGFR2, FGFR3, and FGFR4*, respectively.

HY-109099

Pemigatinib 20+ Cited Publications INCB054828	FGFR	Cancer
Pemigatinib (INCB054828) is an orally active, selective *FGFR* inhibitor with IC₅₀s of 0.4 nM, 0.5 nM, 1.2 nM, 30 nM for FGFR1, FGFR2, FGFR3, FGFR4, respectively. Pemigatinib has the potential for cholangiocarcinoma .

HY-13330

Fexagratinib 30+ Cited Publications AZD4547; ADSK091	FGFR	Cancer
Fexagratinib (AZD4547; ADSK091) is a potent inhibitor of the *FGFR* family with IC₅₀s of 0.2 nM, 2.5 nM, 1.8 nM, and 165 nM for *FGFR1, FGFR2, FGFR3, and FGFR4*, respectively.

HY-100492

Fisogatinib 5 Publications Verification BLU-554	FGFR	Cancer
Fisogatinib (BLU-554) is a potent, highly selective and orally active fibroblast growth factor receptor 4 (FGFR4) inhibitor with an IC₅₀ of 5 nM. Fisogatinib has significant anti-tumor activity in models of hepatocellular carcinoma (HCC) that are dependent on *FGFR4* signalling .

HY-12823

BLU9931 5+ Cited Publications	FGFR	Cancer
BLU9931 is a potent, highly selective, and irreversible fibroblast growth factor receptor 4 (FGFR4) inhibitor with an IC₅₀ of 3 nM and a K_d of 6 nM. BLU9931 has significant antitumor activity .

HY-13304

LY2874455 3 Publications Verification	FGFR	Cancer
LY2874455 is a *pan-FGFR* inhibitor with IC₅₀s of 2.8, 2.6, 6.4, 6 nM for *FGFR1, FGFR2, FGFR3, FGFR4*, respectively.

HY-100019

Rogaratinib 5+ Cited Publications BAY1163877	FGFR	Cancer
Rogaratinib (BAY1163877) is a potent and selective fibroblast growth factor receptor (FGFR) inhibitor. Rogaratinib inhibits FGFRs with IC50s of 11.2 nM (FGFR1), <1 nM (FGFR2), 18.5 nM (FGFR3), 127 nM (VEGFR3/FLT4), 201 nM (FGFR4), respectively .

HY-101568

Roblitinib 5+ Cited Publications FGF-401	FGFR	Cancer
Roblitinib (FGF-401) is an orally active and highly selective *FGFR4* inhibitor with an IC₅₀ of 1.9 nM . Roblitinib has antitumor activity .

HY-101466

E7090	FGFR	Cancer
E7090 is an orally available, potent, and selective *FGFR* inhibitor with IC₅₀s of 0.71 nM, 0.50 nM, 1.2 nM, and 120 nM for *FGFR1/FGFR2/FGFR3/FGFR4*, respectively .

HY-156618

Irpagratinib ABSK011	FGFR	Cancer
Irpagratinib (ABSK011) is an orally active *FGFR4* inhibitor (IC₅₀<10 nM). Irpagratinib inhibits FGFR4 autophosphorylation and blocks signaling from FGFR4 to downstream pathway activation. Irpagratinib has shown high exposure in PK studies in mice, rats, and dogs, and also demonstrated antitumor activity in a subcutaneous xenograft tumor model .

HY-19957

Zoligratinib 3 Publications Verification Debio 1347; CH5183284	FGFR	Cancer
Zoligratinib (Debio 1347) is an orally available and selective *FGFR* inhibitor with IC₅₀s of 9.3, 7.6, and 22 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively.

HY-18602

FIIN-2	FGFR	Cancer
FIIN-2 is an irreversible inhibitor of *FGFR* with an IC₅₀ of 3.1, 4.3, 27, and 45 nM for FGFR1, FGFR2, FGFR3 and FGFR4, respectively.

HY-13311A

Infigratinib phosphate Maximum Cited Publications 47 Publications Verification BGJ-398 phosphate; NVP-BGJ398 phosphate	FGFR	Cancer
Infigratinib phosphate (BGJ-398 phosphate; NVP-BGJ398 phosphate) is a potent inhibitor of the *FGFR* family with IC₅₀ of 0.9 nM, 1.4 nM, 1 nM, and 60 nM for *FGFR1, FGFR2, FGFR3, and FGFR4*, respectively.

HY-101768

PRN1371 1 Publications Verification	FGFR c-Fms	Cancer
PRN1371 is a highly selective and potent *FGFR1-4* and CSF1R inhibitor with IC₅₀s of 0.6, 1.3, 4.1, 19.3 and 8.1 nM for FGFR1, FGFR2, FGFR3, FGFR4 and CSF1R, respectively .

HY-100491

H3B-6527	FGFR	Cancer
H3B-6527 is an orally active, highly selective and covalent *FGFR4* inhibitor with an IC₅₀ of <1.2 nM. H3B-6527 has at least 250-fold selectivity over FGFR1-3 with IC₅₀s of 320 nM, 1290 nM and 1060 nM respectively. H3B-6527 has potent anti-cancer activity .

HY-100631

FGFR4-IN-1 1 Publications Verification	FGFR	Neurological Disease Cancer
FGFR4-IN-1 (example 98) is a potent inhibitor of *FGFR4* with IC₅₀ of 0.4 nM.

HY-P990672

U3-1784 2 Publications Verification	FGFR	Inflammation/Immunology
U3-1784 is a humanized antibody expressed in CHO that targets *FGFR4/CD334*. U3-1784 is equipped with a huIgG1 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for U3-1784 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).

HY-18603

FIIN-3	EGFR FGFR	Cancer
FIIN-3 is an irreversible inhibitor of *FGFR* with an IC₅₀ of 13.1, 21, 31.4, and 35.3 nM for FGFR1, FGFR2, FGFR3 and FGFR4, respectively.

HY-W005118

2-Amino-4-fluoropyridine 4-Fluoropyridin-2-amine	Drug Intermediate	Cancer
2-Amino-4-fluoropyridine (4-Fluoropyridin-2-amine) is a drug intermediate that can be used for the synthesis reversible-covalent FGFR4 inhibitors .

HY-156672

S6K2-IN-1	FGFR	Cancer
S6K2-IN-1 (Compound 2) is a S6K2 inhibitor (IC₅₀: 22 nM). S6K2-IN-1 also inhibits FGFR4 (IC₅₀: 216 nM). S6K2-IN-1 has acceptable stability in mouse liver microsomes .

HY-147515

FGFR4-IN-11	FGFR	Cancer
FGFR4-IN-11 (Compound 30) is a potent, selective, covalent *FGFR4* inhibitor with an IC₅₀ of 2.1 nM. FGFR4-IN-11 significantly inhibits the FGF19/FGFR4 signaling pathway and shows antitumor activity .

HY-163273

FGFR4-IN-17	FGFR	Cancer
FGFR4-IN-17 (Compound (S)-23) is a piperazinyl diflurindan derivative containing pyridinyl. FGFR4-IN-17 is a *FGFR* inhibitor with IC₅₀ values of 24.2, 16.1, 78.0, and 68.0 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively. FGFR4-IN-17 has antitumor activity .

HY-151903S

FGFR2/3-IN-1	FGFR	Cancer
FGFR2/3-IN-1 is a potent and selective FGFR2 and FGFR3 (FGFR) inhibitor with IC₅₀s of 1 nM and 0.5 nM, respectively. FGFR2/3-IN-1 displays >40-fold selectivity over FGFR1/FGFR4 and other kinome. FGFR2/3-IN-1 also inhibits FGFR3 V555L and V555M mutants with IC₅₀s of 2.7 nM and 6.1 nM, respectively .

HY-123134

FIIN-4	FGFR	Cancer
FIIN-4 is a first-in-class, orally active and covalent *FGFR* inhibitor with IC₅₀s of 2.6 nM, 2.6 nM, 5.6 nM, 9.2 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively. FIIN-4 can inhibit metastatic tumor growth.

HY-E70823

FGFR2 N549K Recombinant Human Active Protein Kinase	FGFR	Cancer
FGFR2 is a receptor tyrosine kinase that is involved in many human cancers such as intrahepatic cholangiocarcinomas and hepatocellular carcinomas. FGFR2 N549K is a mutant of FGFR3. FGFR2 N549K Recombinant Human Active Protein Kinase is a recombinant FGFR4 N535K protein that can be used to study FGFR4 N535K-related functions .

HY-13311S

Infigratinib-d3 BGJ-398-d₃; NVP-BGJ398-d₃	FGFR	Cancer
Infigratinib-d3 is a deuterated analog of infigratinib. Infigratinib is an effective inhibitor of the *FGFR* family, with IC₅₀ values of 0.9 nM, 1.4 nM, 1 nM, and 60 nM for *FGFR1, FGFR2, FGFR3, and FGFR4*, respectively .

HY-13330R

Fexagratinib (Standard) AZD4547 (Standard); ADSK091 (Standard)	Reference Standards FGFR	Cancer
Fexagratinib (Standard) is the analytical standard of Fexagratinib. This product is intended for research and analytical applications. Fexagratinib (AZD4547; ADSK091) is a potent inhibitor of the *FGFR* family with IC₅₀s of 0.2 nM, 2.5 nM, 1.8 nM, and 165 nM for *FGFR1, FGFR2, FGFR3, and FGFR4*, respectively.

HY-177276

FGFR-IN-22	FGFR	Cancer
FGFR-IN-22 (Compound 23) is a *FGFR* inhibitor with IC₅₀s of 0.631, 1.26, 0.851 and 1 nM for FGFR1, FGFR2, FGFR3 and FGFR4, respectively. FGFR-IN-22 effectively inhibits cell proliferation that depends on the FGFR1 and FGFR3 signaling pathway. FGFR-IN-22 can be used for cancers such as chronic lymphocytic leukemia (CLL) research .

HY-163527

FGFR-IN-13	FGFR	Cancer
FGFR-IN-13 (compound III-30) is an irreversible covalent fibroblast growth factor receptor (FGFR) inhibitor. FGFR-IN-13 regulates endogenous *FGFR1(IC₅₀*=0.20±0.02 nM) and *FGFR4(IC₅₀*=0.40±0.03 nM) mediated signaling pathways by inhibiting the expression of key proteins. FGFR-IN-13 inhibits total-PARP and Bcl-2 protein expressions, and promote Cleaved-PARP and Bax protein expressions in a dose-dependent manner. FGFR-IN-13 has significant antitumor activity and oral activity .

HY-174154

INCB126503	FGFR	Cancer
INCB126503 is an orally activeM, selective *FGFR2/3* Inhibitor with IC₅₀ values of 70 nM (FGFR1), 2.1 nM (FGFR2), 1.2 nM (FGFR3), 0.92 nM (FGFR3-V555L), 0.85 nM (FGFR3-V555M) and 64 nM (FGFR4). INCB126503 suppresses FGFR signaling in vivo without causing hyperphosphatemia and shows antitumor efficacy in xenograft models harboring FGFR3 genetic alterations .

HY-172787

FGFR4-IN-23	FGFR Akt AMPK	Cancer
FGFR4-IN-23 (compound 48c) is a *FGFR4* inhibitor with an IC₅₀ value of 2.9 nM against *FGFR4* ^WT kinase. FGFR4-IN-23 inhibits the phosphorylation of *FGFR4, AKT* and MAPK .

HY-115902

FGFR4-IN-7	FGFR Apoptosis	Cancer
FGFR4-IN-7 (Compound C3) is a covalent reversible *FGFR4* inhibitor with an IC₅₀ value of 0.42 μM. FGFR4-IN-7 induces apoptosis via the FGFR4 signaling pathway blockage. FGFR4-IN-7 can be used for the research of hepatocellular carcinoma (HCC) .

HY-147793

FGFR4-IN-12	FGFR	Cancer
FGFR4-IN-12 (Compound A34) is a potent inhibitor of *FGFR4. FGFR4-IN-12* exhibits improved FGFR4 inhibitory capability and selectivity and excellent anti-proliferative activities against FGFR4-dependent HCC cell lines. FGFR4-IN-12 has the potential for the research of cancer diseases . FGFR4-IN-12 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-152146

HDAC-IN-50	Apoptosis FGFR HDAC	Cancer
HDAC-IN-50 is a potent and orally active *FGFR* and HDAC dual inhibitor with IC₅₀ values of 0.18, 1.2, 0.46, 1.4, 1.3, 1.6, 2.6, 13 nM for FGFR1, FGFR2, FGFR3, FGFR4, HDAC1, HDAC2, HDAC6, HDAC8, respectively. HDAC-IN-50 induces Apoptosis and cell cycle arrest at G0/G1 phase. HDAC-IN-50 decreases the expression of pFGFR1, pERK, pSTAT3. HDAC-IN-50 shows anti-tumor activity .

HY-170934

BW710	FGFR	Cancer
BW710 is an orally active fibroblast growth factor receptor 2 (FGFR2) inhibitor. BW710 inhibits the proliferation of BaF3-FGFR2 cells with an IC₅₀ of 2.8 nM. BW710 abolishes *FGFR2* enzymatic activity and is selective against other 75 tyrosine kinases including *FGFR1, FGFR3, and FGFR4* at 1 μM. BW710 suppresses the *FGFR2* signaling and selectively inhibits *FGFR2*-driven cancer cell proliferation. BW710 displays reasonable pharmacokinetic properties with an oral bioavailability of 29 % in mice .

HY-145836

FGFR4-IN-8	FGFR	Cancer
FGFR4-IN-8 (Compound 7v) is an ATP-competitive, highly selective covalent inhibitor of wild-type and gatekeeper mutant *FGFR4. FGFR4-IN-8* exhibits excellent potency against FGFR4, FGFR4 ^V550L, FGFR4 ^V550M and FGFR4 ^C552S with IC₅₀s of 0.5, 0.25, 1.6, 931 nM, respectively. FGFR4-IN-8 exhibits potent antiproliferative activity against Hep3B hepatocellular carcinoma cells with the IC₅₀ value of 29 nM. FGFR4-IN-8 demonstrates modest in vivo antitumor efficacy in nude mice bearing the Huh-7 xenograft model .

HY-170690

FGFR4-IN-22	FGFR	Cancer
FGFR4-IN-22 (compound 10f) is a potent inhibitor of *FGFR4, with the IC₅₀* of 5.4 nM. FGFR4-IN-22 serve as a potential lead compound targeting FGFR4 for anti-HCC agent development .

HY-161610

FGFR4-IN-21	FGFR	Cancer
FGFR4-IN-21 (Compd 4c) is a *FGFR4* inhibitor with an IC₅₀ of 33 nM. FGFR4-IN-21 can be used for hepatocellular carcinoma research .

HY-178059

FGFR-IN-23	FGFR p38 MAPK Akt ERK Apoptosis	Cancer
FGFR-IN-23 (Compound 9p) is a covalent pan *FGFR* inhibitor with IC₅₀s of 14, 4.2, 5 and 220 nM for FGFR1, FGFR2, FGFR3 and FGFR4, respectively. FGFR-IN-23 also has potent inhibitory activity against gatekeeper mutants, such as FGFR1 ^V561M and FGFR3 ^V555M. FGFR-IN-23 suppresses the activation of FGFR-mediated signaling and induces apoptosis. FGFR-IN-23 shows significant antitumor efficacy in RT112 xenograft mouse models. FGFR-IN-23 can be used for cancers and its drug resistance research .

HY-163569

FGFR4-IN-20	FGFR	Cancer
FGFR4-IN-20 (comp 11) is an orally active and selective *FGFR4* inhibitor with IC₅₀s of 19 and 36 nM against Huh7 cells and FGFR4 enzyme. FGFR4-IN-20 can be used for hepatocellular carcinoma research .

HY-144759

FGFR4-IN-9	FGFR	Cancer
FGFR4-IN-9 (Compound 6O) is a selective *FGFR4* inhibitor with an IC₅₀ of 75.3 nM. FGFR4-IN-9 effectively inhibits both the growth and angiogenesis of HCC .

HY-158248

FGFR4-IN-19	FGFR	Cancer
FGFR4-IN-19 (compound 8B) is a potent covalent fibroblast growth factor receptor 4 (FGFR4) inhibitor (IC₅₀=1.2 nM). FGFR4-IN-19 achieves high efficiency and isotype selectivity by covalently targeting a rare cysteine (C552) in the *FGFR4* kinase domain. FGFR4-IN-19 can be used for hepatocellular carcinoma (HCC) research .

HY-156704

FGFR4-IN-16	FGFR	Cancer
FGFR4-IN-16 (CY-15-2) is a covalent inhibitor of *FGFR-4* for cancer research .

HY-131704

FGFR4-IN-5	FGFR	Cancer
FGFR4-IN-5 is a potent and selective covalent *FGFR4* inhibitor with an IC₅₀ of 6.5 nM. FGFR4-IN-5 exhibits strong anti-tumor activity in vivo and can be used for hepatocellular carcinoma research .

HY-155046

FGFR4-IN-14	FGFR	Cancer
FGFR4-IN-14 (Compound 27i) is a *FGFR4* inhibitor (IC₅₀: 2.4 nM. FGFR4-IN-14 inhibits the proliferation of V550L and N535K mutant strains, with IC₅₀s of 21 nM, 2.5 nM, 171 nM against huh7, BaF3/ETV6-FGFR4-V550L and BaF3/ETV6-FGFR4-N535K cells respectively. FGFR4-IN-14 has potent antitumor efficacy in the Huh7 xenograft model. FGFR4-IN-14 can be used for research of hepatocellular carcinoma (HCC) .

HY-E70722

FGFR4 V550E Recombinant Human Active Protein Kinase	FGFR	Cancer
FGFR4 is a transcriptional target of the PAX3-FOXO1 fusion gene. FGFR4 expression is significantly higher in rhabdomyosarcoma. FGFR4 V550E is a mutant of FGFR3 that may be present in rhabdomyosarcoma. FGFR4 V550E Recombinant Human Active Protein Kinase is a recombinant FGFR4 V550E protein that can be used to study FGFR4 V550EK-related functions .

HY-162283

FGFR4-IN-18	FGFR	Cancer
FGFR4-IN-18 (compound 8z) is an inhibitor of FGFR4 and can be used in cancer research .

HY-146541

FGFR4-IN-10	FGFR	Cancer
FGFR4-IN-10 (compound 5a) is a potent and selective *FGFR4* inhibitor with an IC₅₀ value of 70.7 nM. FGFR4-IN-10 shows no inhibition against other FGFR family members, i.e. FGFR1, FGFR2 and FGFR3 .

HY-129181

FGFR4-IN-4	FGFR	Cancer
FGFR4-IN-4 (compound 693) is a *FGFR4* inhibitor with anti-tumor activity, extracted from patent WO2018113584A1 .

HY-E70721

FGFR4 N535K Recombinant Human Active Protein Kinase	FGFR	Cancer
FGFR4 is a transcriptional target of the PAX3-FOXO1 fusion gene. FGFR4 expression is significantly higher in rhabdomyosarcoma. FGFR3 K650E is a mutant of FGFR3 that may be present in rhabdomyosarcoma. FGFR4 N535K Recombinant Human Active Protein Kinase is a recombinant FGFR4 N535K protein that can be used to study FGFR4 N535K-related functions .

Cat. No.	Product Name	Target	Research Area	Image

HY-P990672

U3-1784 2 Publications Verification	FGFR	Inflammation/Immunology
U3-1784 is a humanized antibody expressed in CHO that targets *FGFR4/CD334*. U3-1784 is equipped with a huIgG1 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for U3-1784 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).

Cat. No.	Product Name	Chemical Structure

HY-151903S

FGFR2/3-IN-1
FGFR2/3-IN-1 is a potent and selective FGFR2 and FGFR3 (FGFR) inhibitor with IC₅₀s of 1 nM and 0.5 nM, respectively. FGFR2/3-IN-1 displays >40-fold selectivity over FGFR1/FGFR4 and other kinome. FGFR2/3-IN-1 also inhibits FGFR3 V555L and V555M mutants with IC₅₀s of 2.7 nM and 6.1 nM, respectively .

HY-13311S

Infigratinib-d3
Infigratinib-d3 is a deuterated analog of infigratinib. Infigratinib is an effective inhibitor of the *FGFR* family, with IC₅₀ values of 0.9 nM, 1.4 nM, 1 nM, and 60 nM for *FGFR1, FGFR2, FGFR3, and FGFR4*, respectively .

HY-W754878

Pemigatinib-d6
Pemigatinib-d₆ (INCB054828-d₆) is deuterium labeled Pemigatinib. Pemigatinib (INCB054828) is an orally active, selective *FGFR* inhibitor with IC₅₀s of 0.4 nM, 0.5 nM, 1.2 nM, 30 nM for FGFR1, FGFR2, FGFR3, FGFR4, respectively. Pemigatinib has the potential for cholangiocarcinoma .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: